Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.
Natalia Mena VázquezFrancisco Javier Godoy-NavarreteSara Manrique-ArijaMaría Carmen Aguilar-HurtadoCarmen María Romero-BarcoInmaculada Ureña-GarnicaF EspildoraIsabel Añón-OñateLorena Pérez-AlbaladejoCarmen Gomez-CanoFrancisco Gabriel Jimenez-NúñezMaría Isabel Padin-MartínAntonio Fernández-NebroPublished in: Clinical rheumatology (2020)
Lung function is stable and inflammatory activity well controlled in most patients with RA-ILD receiving treatment with DMARDs. Non-anti-TNF DMARDs reduce the risk of worsening of lung disease in 90% of patients. The inflammatory activity of RA and smoking, on the other hand, are associated with worsening. Key Points • We have performed prospectively evaluated lung and joint function in patients with RA-ILD receiving treatment with various DMARDs. • In our study, the lung function is stable and inflammatory activity well controlled in most patients with RA-ILD receiving treatment with DMARDs. • Neither csDMARDs nor anti-TNF agents were associated with a significant risk of worsening of lung disease, whereas non-anti-TNF bDMARDs could reduce the risk of worsening of lung disease. • Smoking and poor control of joint involvement were the main factors associated with worsening of lung disease.
Keyphrases
- rheumatoid arthritis
- interstitial lung disease
- lung function
- disease activity
- systemic sclerosis
- rheumatoid arthritis patients
- ankylosing spondylitis
- chronic obstructive pulmonary disease
- cystic fibrosis
- idiopathic pulmonary fibrosis
- oxidative stress
- air pollution
- ejection fraction
- smoking cessation
- systemic lupus erythematosus
- combination therapy